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Histopathologic analysis remains a major tool in comparative molecular carcinogenesis. In the last decade, however, there has been increased emphasis on the molecular analysis of critical target genes in developing an understanding of the etiology of cancer, determining the prognosis of specific cancers, and in discovering new potential therapeutic intervention strategies. A driving force behind the recent emphasis on molecular analysis is the premise that the most useful animal models should mimic or recapitulate human disease. Consequently, study of molecular alterations in animal models of cancer should strengthen the ability to extrapolate from animals to humans and, in addition, may provide important molecular clues to help understand the mechanistic underpinnings of human cancer. Many of the available and emerging molecular techniques for studying cancer, summarized by Dr. David Malarkey, lend themselves to slide-based analysis and are, therefore, of special interest to toxicologic pathologists. Important themes emphasized by the speakers include (a) extreme complexity of molecular events in carcinogenesis, (b) complications associated with making interspecies comparisons, (c) advantages of studying comparative molecular carcinogenesis, (d) major similarities and differences between human and animal cancers, and (e) implications of animal models in human risk assessment.
The fact that the efforts involved in studying the molecular basis of mammalian cancer have taken longer than initially anticipated was underscored in Dr. Peter Nowell's overview in which he described the accumulation of mutations in growth regulatory genes throughout the complex process of clonal expansion. He pointed out that more than 30 yr were necessary to elucidate the 1, 2, or though alterations in some protooncogenes such as ras, myc, and bcl-2 have been implicated in human cancers, the majority of solid human tumors do not have identified protooncogene alterations. In addition to involvement of multiple genes in the carcinogenic process, there are multiple pathways to cancer induction, multiple etiologies, important temporal differences in induction of cancer in short-lived animal models versus humans, susceptibility factors that must be considered, and still a relative lack of knowledge of the complexities of carcinogenesis.
Given the enormous complexity of carcinogenesis and our relative immature state of knowledge, it is reasonable to ask, &dquo;Why would we wish to study the comparative molecular biology of cancer?&dquo; The simple answer is to (a) elucidate common molecular alterations in different cancers, (b) identify etiologies of specific cancers, and (c) improve the animal models used to study cancer induction. If the same gene is altered in most tumors of a given type in different species, a critical role for that gene in growth control of normal or malignant cells is implied. Study of a given gene involved in carcinogenesis has frequently paved the way to developing an understanding of the function of that gene, not only in the cancer process, but also in normal tissues. Once the biochemical functions of different genes are understood, observed patterns of molecular alterations should be even more helpful. Alterations (e.g., mutations, increased expression) in different genes in the same pathway may provide important clues to biological changes that occur during tumor progression and, at the same time, provide some of the mechanistic data that Dr. Kenneth Hastings indicated as important in assessing human risk.
Molecular studies may help identify etiologies and provide molecular fingerprints of specific cancers. For example, the 50% frequency of G ~ T mutations in codon 249 of p53 in human hepatocellular carcinomas implicates environmental exposure to aflatoxin B 1 in liver cancer induction. Similar molecular fingerprints have been identified in ras activation for methylnitrosourea (MNU)induced rat mammary cancer, dimethylbenzanthraceneinduced mouse skin and liver cancer, and N-hydroxyl-2acetylaminofluoreneas well as benzidine-induced mouse liver tumors. Although finding such molecular fingerprints is encouraging, many more genetic alterations are typically required for the induction and progression of even these apparently etiology-specific cancers.
Molecular biology is a new metric to measure animal models against human cancer counterparts. Because human cancers are heterogeneous, like the human population, probably no single animal model will suffice as a totally appropriate surrogate for studying a specific human cancer. Rather, every animal model can provide insights into certain elements of cancer. For example, considerable effort has been expended in studying alterations in the ras protooncogenes in human and animal cancers. While activation of ras protooncogenes occurs in approximately 90% of human pancreatic cancers and in 95% of experimentally induced hamster pancreatic cancers, the lack of concordance of ras activation between human breast cancer (2%) and experimentally induced rat mammary cancer (80-100%) suggests that important in-terspecies differences exist. In general, ras protooncogene activation occurs more frequently in spontaneous and experimentally induced rodent cancers than in human cancers. On the other hand, p53 is purported to be the most frequently altered gene in a variety of human cancers, yet p53 alterations are, in general, infrequent in animal cancers. Even here exceptions occur. For example, p53 mutations are seen in 40% of butadiene-induced mouse mammary tumors and in 10-25 °70 of methylene chlorideand butadiene-induced mouse pulmonary adenocarcinomas. In his presentation Dr. Recio reported that 5/1 of formaldehyde-induced rat nasal carcinomas had point mutations in p53. Understanding the basis for such species similarities and differences should help in unraveling the complexities of carcinogenesis.
Major molecular differences between animal and human cancers are not surprising because cancers are heterogeneous and can evolve by different pathways in all species, there is a large spectrum of means by which a gene can be altered, and genes involved in cancer can be in any part of stimulatory or inhibitory pathways. Furthermore, etiologic factors influence molecular alterations in specific cancers in all species. The molecular differences in human and animal cancers do not represent fundamental differences in cancer biology. Rather, these changes are consequences of the multiple pathways and etiologic factors that, in addition to carcinogen dose, intrinsic genetic susceptibilities, and age-related factors, influence molecular alterations.
Dr. Cheryl Walker discussed the importance of comparing the same biological stages of cancer in animal models and humans. As examples she mentioned that ras protooncogene alteration is an early event and p53 alteration a late event in epidermal squamous cell carcinoma. In contrast, alteration in p53 is an early event in astrocytoma. Thus, the toxicologic pathologist has an obvious role in assessing the stages of the cancer process and providing guidance to the molecular biologist.
One important observation in rodent tumor models is that the dose of carcinogen may influence the frequency of specific molecular alterations in phenotypically identical tumors. This phenomenon has been reported in mouse liver tumors induced by diethylnitrosamine and vinyl carbamate, in MNU-induced rat mammary tumors, and in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanoneinduced mouse lung tumors and was described by Dr. Ledwith as occurring in CD-1 mice given single versus multiple doses of carcinogen. In all of these examples, both low and high carcinogen doses produced larger numbers of tumors, and the higher dose of carcinogen was consistently associated with a lower frequency of ras activation. This finding is especially significant because it (a) provides molecular evidence that the pathways to cancer induction may differ as a function of carcinogen dose and (b) challenges the assumption that cancer induction is similar at high and low doses. The latter point has important implications for risk assessment. That different etiologic agents produce different molecular alterations in phenotypically identical experimentally induced animal tumors has been most extensively demonstrated for chemically induced mouse liver tumors. Some agents, such as N-hydroxyl-2-acetylaminofluorene, induce mouse liver tumors with a 100% frequency of ras protooncogene activation. Other murine hepatocarcinogens, such as phenobarbital and chlordane, have a 0-7% or 0% frequency of ras activation, respectively. Ras activation frequencies intermediate between these extremes have been reported for a large number of murine hepatocarcinogens. In addition, some murine hepatocarcinogens produce novel point mutations not seen in spontaneous liver tumors, suggesting that there are occasionally agent-specific molecular alterations in animal cancers. This phenomenon is analogous to the &dquo;signature muta-tions&dquo; in p53 seen in human liver cancers associated with environmental exposure to aflatoxin B 1 and to ultraviolet light-induced skin cancers, both of which were discussed by Dr. Recio. Furthermore, frequencies and patterns of molecular alterations in chemically induced cancers allow distinction of these tumors from phenotypically identical spontaneous tumors as emphasized in the presentation by Dr. Ledwith. Examples of molecular alterations in tumors induced by the same etiologic agent in both animals and humans are rare because of the difficulty in ascribing etiology in most human cancers. Noteworthy exceptions are radiation-induced thyroid cancers in both humans and rats characterized by activation of K-ras, G ~ T mutations in aflatoxin B 1-induced tumors in humans and rats, and similar K-ras mutations in lung tumors of smokers and those induced in mice by tobacco-specific carcinogens. It is also noteworthy that, even with the same etiology within a given animal model, multiple individual cancers within an organ are characterized by independent molecular alterations, further frustrating our understanding of the complexities of carcinogenesis.
While patterns of molecular alterations in cancer are influenced by etiologic factors, genetic susceptibility, and dose of carcinogen, additional features of molecular genetics such as genetic conservation, genetic redundancy, and genetic parsimony must be considered. Dr. Walker very aptly described how critical molecular targets are highly conserved throughout evolution, indicating that highly conserved genetic factors underscore the critical importance of specific genes, provide the most fruitful areas for research in carcinogenesis, and justify use of animal models and extrapolation of findings to human cancer. A specific example of genetic conservation important in animal models as well as in human cancer was provided by Dr. Barbara Davis in her presentation of current research activities with the recently identified BRCA-1 and BRCA-2 genes that are important in mammary, ovarian, and probably several other types of human cancer. The fact that multiple redundancies exist in the genetic blueprint is illustrated by the host of different stimuli that can trigger the signal transduction cascade and lead to uncontrolled cell growth. This very redundancy is what make cancer a disease of multiple genetic and molecular events. A pivotal role of p53 in either triggering cellular arrest or apoptosis is illustrative of genetic parsimony where a singular molecular factor can play an important role in diverse functions. Dr. Fredrickson's explanation of ablation of FAS leading to either T-cell lymphoma or late onset plasmacytoma provided another ex-ample of genetic parsimony wherein one molecular factor can lead to different cancer outcomes.
Intrinsic genetic susceptibilities are involved in molecular alterations seen in both human and animal cancers. This phenomenon of differential spontaneous and chemically induced liver tumor susceptibilities among different mouse strains has been known for years and is attributed to differences in the existence of susceptibility loci not fully characterized Both Dr. Fox and Dr. Ledwith mentioned that the frequency of ras protooncogene activation is generally greater in liver tumor susceptible than in liver tumor resistant mouse strains. Similar genetic susceptibility to cancer is well known in humans with inherited alterations in the retinoblastoma gene, the Wilm's tumor gene, and in p53 (Li-Fraumeni syndrome) . Such genetically susceptible human populations may be especially sensitive to environmental factors as seen in xeroderma pigmentosa patients who develop skin cancer when exposed to sunlight. Dr. Walker presented her work with the Eker rat model which develops spontaneous renal cell cancers that are increased many-fold by exposure to carcinogens. The Eker rat is being used as a model to study human von Hippel-Lindau disease, an inherited predisposition to development of renal cancer associated with alterations in the von Hippel-Lindau (VHL) tumor suppressor gene. Although the Eker rat does not appear to have alterations in the VHL gene, other molecular alterations in their renal tumors are being investigated. Dr. Walker stressed that exploring the molecular differences and similarities between animal models, such as the Eker rat, and related susceptible human populations should provide important clues to understanding the cancer process.
An additional factor in understanding molecular aspects of carcinogenesis is related to age and time differences in animal versus human cancer induction. Because rodent models develop cancer in 1-2 yr versus 40-80 yr in humans, that age may play an important role in carcinogenesis between animals and humans is suggested. Werner syndrome, a premature aging disease in humans, is associated with the early appearance of cancer, suggesting a connection between genes related to aging and those involved in carcinogenesis. In vitro studies have shown that rodent cells, in contrast to human cells, have an enhanced ability to escape replicative senescence and become replicatively immortal, either spontaneously or following exposure to carcinogens, suggesting that senescence or aging genes may be associated with the induction of cancer. Active study of senescence is underway in the hope that important molecular links can be found between this process and its role in cancer development in rodent models and humans.
Virtually all of the speakers either stated or implied that exploration of molecular similarities and differences between animal cancer models and human cancers should continue if we hope to unravel the complexities of cancer and find novel means of overcoming this important human malady. While no one animal model appears to offer the key to solving the mysteries of cancer, every model can provide some insights into certain elements of carcinogenesis. The take-away message from this symposium is that cancer is, indeed, extremely complex. There are multiple etiologies, multiple pathways, multiple stages and steps, multiple genetic alterations, and multiple mechanisms and factors contributing to this complexity. While studying only I or 2 of these factors, variables, or molecular alterations will probably not be enough to make substantial headway in understanding carcinogen-esis, the ever-increasing national and international collaboration is allowing many scientists to contribute their specific expertise to teasing out the underpinnings of cancer. Pathologists have played and will continue to play a critical role in this process as we focus on the most critical molecular targets in the carcinogenic process.
